Gray market peptides: what the FDA panel reviewed

In July 2026 an FDA advisory panel voted to recommend that six of seven peptides it reviewed could be made by compounding pharmacies. The six were BPC-157, MOTS-c, KPV, TB-500, Epitalon and Semax. Reviewers also said that large, controlled human trials are missing, and that in some cases no published human studies exist. The vote was advice, not a final regulatory decision.

What did the FDA advisory committee decide about peptides?

According to NPR’s report, the panel met for two days and reviewed seven peptide therapies. It voted in favour of reclassifying six of them, potentially allowing specialised pharmacies in the United States to produce them. Only emideltide, which is used for insomnia, received a vote against.

Today these peptides cannot be legally manufactured in the US outside of research, which NPR reports has pushed users toward unvetted online purchases. Coverage in Medscape carries the headline “so much hype, so little data”.

Two details about the process were widely noted. Eight new panel members were appointed before the meeting, most with ties to the peptide industry, per NPR. And an FDA official, Russell Wesdyk, explained a core difficulty: quality standards cannot be set until it is clear what the products actually are, since they appear in many different forms.

What does the evidence on these peptides look like?

Thin. Scientists at the meeting raised reservations about the lack of rigorous human data. The compounds lack the large, well-controlled human trials normally needed for drug approval. Safety concerns discussed included the potential to encourage cancer growth and the possibility of a massive immune response. In some cases there were no published human clinical studies at all.

Dr Elizabeth Rebello, quoted by NPR, said she was concerned that the decision responded to market-induced demand rather than solid science.

Two distinctions are useful. Popularity is not evidence: a compound can be widely discussed online while having almost no human trial data. And a recommendation to allow compounding is a decision about access and manufacturing quality, not a finding that the products work.

For anyone reading about a peptide, the practical questions are what human trials exist, how large they were, what was measured, and who funded them. Those are the same questions this blog applies to every claim, from supplements to screening tests.

The bottom line

• An FDA advisory panel voted in July 2026 to recommend six of seven reviewed peptides (BPC-157, MOTS-c, KPV, TB-500, Epitalon, Semax) for compounding; emideltide received a vote against.
• Reviewers noted a lack of large, controlled human trials, and in some cases no published human studies.
• The panel’s vote is advisory, and a decision on access is not evidence of efficacy.